Top Tweets for #mPDAC
The #daraxonrasib data in #mPDAC at #ASCO26 is incredible (HR 0.40, doubling of OS), but it points to a much larger structural need in oncology.
We need to rapidly expand pan-cancer, molecularly designed basket trials. #TAPUR laid the foundation, but to truly capitalize on these targeted agents across histologies, we need more of that infrastructure. The biology is demanding it!
#ASCO26 @NazliDizman @IbrahimAzarOnc @Dr_Crazy94 @OncoAlert @montypal @SPremji7866 @IMG_Oncologists @DrChoueiri @jrgralow @FionnualaCrowle @ja_ocejo @noha_soror @royaryam @OncoAlert @OncBrothers @crisbergerot @PauloBergerot @realbowtiedoc @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @jgong15 @DrSAHaddad @GIMedOnc @iandresmeraz @SakditadMD @RamilaShilpakar @AnaVManana @AmandaNizamMD
Moments like today at #ASCO26 remind you why oncology is such an extraordinary field. What an absolute privilege to witness advances like #RASOLUTE-302 in real time. #RAS_ON @MSK_DeptOfMed @RevMedicines @DanaFarber #mPDAC
This is not simply a new pancreatic cancer drug.
It is a reminder that even “undruggable” biology can become treatable with persistence.
Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists
Ph1/2 #Daraxonrasib monotherspy in 1L #mPDAC:
Significant % any-grade TRAE for rash, diarrhoea and mucositis but few (10%) grade 3. Additionally, with mFU of ~14m, 70% required dose modifications and only 3% discontinued.
Great outcomes for a Ph1/2. ORR 51%, DCR 97%, ctDNA clearance 57% in evaluable pts. In ITT, 6mPFS 71% & 6mOS 83%.
Is PDAC the new UC? @tompowles1
#PancreaticCancer #Pancreas
https://t.co/At11tszr8L
❇️ At @ASCO #GI25, we spoke with Dr. @MaenAbdelrahim on the impact of UGT1A1*28 in patients with #mPDAC who were treated with #NALIRIFOX during NAPOLI 3.
📺 Does UGT1A1*28 status affect safety or dosing in patients? Watch the full interview to find out: https://t.co/Rq8TnpMV5W
*FDA Type C mtg 1H25 for clearance of the Company-sponsored #mPDAC P1 trial
*data readout 4Q24 from NIH's National Eye Inst-funded REAGIR P3 trial of Bascom Palmer's Rose Bengal PDAT
-pursue pre-IND submission mtg 1H25
-$3 million seed money, $20-$33 million valuation
$PVCT
$PVCT Fourth Quarter 2024 Investor Update presentation slides https://t.co/oZICu8956X #RoseBengal #RoseBengalSodium #Provectus
Great presentation on the #GIANTstudy at #ASCO24 today by GI CONNECT member @efratdotan, providing important data to guide treatment decisions in vulnerable older patients with treatment naïve #mPDAC.
Check out the abstract here 👇
https://t.co/pZiMypZjVD
#MedEd #Oncology
The U.S. Food and Drug Administration has approved Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil, and leucovorin as a first-line treatment for adults living with metastatic pancreatic adenocarcinoma #mPDAC #CheckRare #RareDisease
https://t.co/BF5x4I92W6
NALIRIFOX represents a potential new first-line standard of care for patients with metastatic pancreatic ductal adenocarcinoma. @UniVerona @MelisiDavide #oncology #mPDAC https://t.co/bCAu4iIEil
Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC) @ASCO. @MPishvaian @edikb @PanCAN #mPDAC #ASCO23 #Perthera #PrecisionMedicine
Great news‼️ #mPDAC
📣 On the ground at @ASCO #GI23: results from NAPOLI-3, co-authored by VHIO’s @MacarullaTeresa @vallhebron, show 1st line NALIRIFOX improved overall survival vs. standard therapy in treatment-naïve patients with mPDAC.
➕ https://t.co/c2BgfBe9lm
NAPOLI 3 results are finally in! 🚨
Median OS of 11.1 mo with NALIRIFOX vs 9.2 mo with Gem+NabP in #mPDAC
HR 0.84 (0.71, 0.99) p = 0.04
New standard of care?
@PanCAN @letswinpc @OncoAlert @NatPancFdn @OHSUpancreatic
The PRINCE Trial uncovered various predictive biomarkers associated with longer OS for certain patients with #mPDAC - which has a 5-year survival rate of <5%.
🟢Happening now:
Distinct biosignatures associate with survival after 1L Chemo-IO in patients with #mPDAC #PCSM #PRINCEtrial Immuno-Pharmacodynamic effect. #ASCO22 #ASCO22CM
@EileenMOReilly @GABOUALFA
#AccernAlert Pivotal Ph3 Napoli1 (Onivyde+5FU) $MACK #ESMO16 #mPDAC 1 in 4 survived 1yr or &lt; (+26% survival vs.16 receiving Onivy #stocks
Last Seen Hashtags on Sotwe
นัดเย็ดเพชรบูรณ์
Seen from Thailand
tooearlytotravel
Seen from United Kingdom
Indonesiangirls
扫楼
Seen from United States
cakednani
Seen from United States
御姐
Seen from United States
crossdresser #mature
Seen from Turkey
voteoutmaxmiller
Seen from United States
FalkirkScienceFestival
Seen from United States
wherethesunis
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.3M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.7M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.7M followers
KATY PERRY
@katyperry
87.2M followers
Taylor Swift
@taylorswift13
81M followers
Lady Gaga
@ladygaga
72.6M followers
Kim Kardashian
@kimkardashian
69.6M followers
Virat Kohli
@imvkohli
69.2M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.6M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.8M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.3M followers